A O’Farrell

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

A O’Farrell, James M. Foran, Walter Fiedler et al. · PubMed · 2003 · 311 citations

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

Lesley Murray, Tinya J. Abrams, Kelly R. Long et al. · Clinical & Experimental Metastasis · 2003 · 304 citations

Csf-1r-dependent Osteolysis, Sclerostin, Breast Cancer +8

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

Walter Fiedler, Rolf M. Mesters, Heike Tinnefeld et al. · Blood · 2003 · 263 citations · Full text

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

Kevin Yee, A O’Farrell, Beverly D. Smolich et al. · Blood · 2002 · 164 citations

A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657

Jastinder Sohal, Vernon T. Phan, Philip V. Chan et al. · Blood · 2003 · 106 citations · Full text